The Finnish firm provided updates on its isothermal amplification-based molecular diagnostics technology as well as its broader diagnostics business.
The firm said the point-of-care test would help clinicians rapidly decide whether an upper respiratory infection is viral, bacterial, or clinically insignificant.
The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.
The University of Illinois team developed the technology with an eye at low-resource settings, including developing nations and rural communities.
The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The clearance provides clinicians in emergency departments, intensive care, and other hospital units with a tool for antibiotic stewardship.
The firm said that its Panther Fusion system expands molecular testing capabilities, and increases productivity and flexibility for labs.
The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
The firm expects that revenues from ePlex installations at US customer sites will positively impact its financial results for the second half of 2017.
The test, which runs directly from a patient nasopharyngeal swab, is the fifth assay on the firm's sample-to-result molecular diagnostics platform.